Immunological Strategies Against Porphyromonas gingivalis-Induced Periodontal Disease

Porphyromonas gingivalis is recognised as a keystone pathogen in chronic periodontitis, driving a dysbiotic shift in the subgingival microbiome and promoting destructive inflammation. Immunological strategies against P. gingivalis centre on both modulation of innate defences and induction of pathogen-specific adaptive responses. Innate approaches include targeting pattern-recognition receptors on epithelial cells and dendritic cells to recalibrate inflammatory signalling and preserve tissue homeostasis. Adaptive strategies focus on eliciting protective antibodies against key virulence factors such as gingipains, fimbrial proteins and capsular polysaccharides. Vaccine platforms under investigation range from subunit constructs with recombinant antigens and built-in adjuvants to conjugate formulations that enhance T-cell help and high-affinity memory. Mucosal immunisation via nasal or oral routes aims to induce secretory IgA in saliva and gingival crevicular fluid, thereby preventing bacterial colonisation and biofilm formation. Systemic vaccination principally elicits IgG isotypes capable of neutralising proteolytic enzymes and blocking bacterial adherence. Recent advances in immunomodulatory adjuvants, multiepitope design and carrier systems have supported the development of formulations that balance Th1/Th2 responses, promote long-term memory and mitigate potential immunopathology. Collectively, these immunological interventions hold promise as adjuncts to mechanical debridement and antimicrobial therapy, with the goal of preventing alveolar bone loss and preserving periodontal health.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Immunological Strategies Against Porphyromonas gingivalis-Induced Periodontal Disease publication trend

The graph below shows the total number of articles in immunological strategies against porphyromonas gingivalis-induced periodontal disease across all publications each year (not limited to Nature Index journals).

Technical terms

Adjuvant: A substance co-administered with antigens to enhance the magnitude and quality of the immune response.

Secretory IgA (SIgA): An antibody isotype predominant at mucosal surfaces that prevents pathogen attachment and neutralises toxins.

Gingipains: Cysteine proteases produced by P. gingivalis that degrade host proteins and modulate immune signalling.

Fimbriae: Hair-like surface structures on P. gingivalis responsible for adhesion, biofilm formation and host-cell interactions.

Conjugate vaccine: A formulation in which a polysaccharide antigen is covalently linked to a protein carrier to induce T-cell dependent immunity.

Th1/Th2 response: Polarised T-helper cell pathways that direct cellular (Th1) or humoral (Th2) immunity through distinct cytokine profiles.

References

1. A built-in adjuvant-engineered mucosal vaccine against dysbiotic periodontal diseases. Mucosal Immunology (2018).
2. A therapeutic Porphyromonas gingivalis gingipain vaccine induces neutralising IgG1 antibodies that protect against experimental periodontitis. npj Vaccines (2016).
3. Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities. Frontiers in Immunology (2021).
4. A Porphyromonas gingivalis Capsule-Conjugate Vaccine Protects From Experimental Oral Bone Loss. Frontiers in Oral Health (2021).
5. Porphyromonas gingivalis Vaccine: Antigens and Mucosal Adjuvants. Vaccines (2024).